Rheumatology Advance Access originally published online on February 20, 2006
Rheumatology 2006 45(8):1005-1008; doi:10.1093/rheumatology/kei211
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease
Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Patras, Greece.
Correspondence to: S. N. C. Liossis, Department of Internal Medicine, Division of Rheumatology, Patras University Hospital, 26504 Rion, Patras, Greece. E-mail: sliossis{at}med.upatras.gr
Objective. To find an effective, safe immunosuppressive regimen as an alternative to cyclophosphamide (Cy) for the treatment of clinically evident diffuse scleroderma (dSSc)-associated alveolitis of recent onset.
Methods. Five consecutive patients with dSSc and recent-onset alveolitis were enrolled and treated with mycophenolate mofetil (MMF) and small (
10 mg/day) doses of predinisolone in this open-label trial. One patient with long-standing fibrosing alveolitis was later added to our cohort. Pulmonary function tests [carbon monoxide diffusing capacity (DLCO) and forced vital capacity (FVC)], pulmonary high-resolution computed tomography (HRCT) scans and clinical assessment were performed before and at specified time-points after enrolment. Cases of significant infections, leucopenia and abdominal pain were recorded.
Results. After 4–6 months of MMF therapy, DLCO improved significantly compared with pre-treatment (mean DLCO 75.4% vs 64.2% of predicted value, respectively, P=0.033). Values of FVC also improved, with the difference almost reaching levels of statistical significance (mean FVC 76.2% vs 65.6% of predicted value, P=0.057). Ground glass opacities cleared in three of four patients with recent-onset alveolitis and were reduced in one patient after 6–8 months of treatment. Breathlessness and cough improved by 3 months. A possible treatment failure was seen in one patient. However, in five patients functional and clinical improvement was sustained during the study period. No adverse events were recorded in this ongoing clinical trial.
Conclusion. Our preliminary data suggest that in patients with dSSc and recent, clinically apparent alveolitis, early treatment with MMF and small doses of corticosteroids (CS) may represent an effective, well-tolerated and safe alternative therapy.
KEY WORDS: Diffuse scleroderma, Alveolitis, Mycophenolate mofetil
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. U. Wells, V. Steen, and G. Valentini Pulmonary complications: one of the most challenging complications of systemic sclerosis Rheumatology, June 1, 2009; 48(suppl_3): iii40 - iii44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Daoussis, S.-N. C. Liossis, A. C. Tsamandas, C. Kalogeropoulou, A. Kazantzi, C. Sirinian, M. Karampetsou, G. Yiannopoulos, and A. P. Andonopoulos Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study Rheumatology, May 15, 2009; (2009) kep093v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Sabnani, M. J. Zucker, E. D. Rosenstein, D. A. Baran, L. H. Arroyo, P. Tsang, M. Zubair, and V. Rivera A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide Rheumatology, January 1, 2009; 48(1): 49 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kim and K. C. Meyer Review: Therapies for interstitial lung disease: past, present and future Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 319 - 338. [Abstract] [PDF]
|
|
|
|
|
|
S. C. Plastiras, P. G. Vlachoyiannopoulos, and G. E. Tzelepis Mycophenolate mofetil for interstitial lung disease in scleroderma Rheumatology, December 1, 2006; 45(12): 1572 - 1572. [Full Text] [PDF]
|
|